On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, ...

Nukkleus Inc. has partnered with Translink Corporate Finance to identify acquisition opportunities in the air defense sector, leveraging Translink's extensive expertise in mergers and acquisitions.

The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of the submission finalists' projects succeeded in meeting the ...

AZ and Amgen tried and failed to develop tezepelumab as a therapy for atopic dermatitis, chalking up one failed phase 3 trial in 2017, but have continued to develop the drug for other indications ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

A weekly programme that illuminates the mysteries and challenges the controversies behind the science that's changing our world.